Hoth Therapeutics, Inc. announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.

HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease (AD). AD is a neurodegenerative disease that is characterized by aggregates of amyloid ß (Aß) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia. The initial experiments, conducted by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine, focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aß in the brain interstitial fluid, using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice).

The initial data from these studies shows a significant decrease in Aß in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aß levels, supporting that HT-ALZ has the potential to modify Aß plaque formation in the brain and be developed as an AD therapeutic.